SRAMF (Sisram Medical) Total Stockholders Equity: $479.9 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SRAMF Sisram Medical Ltd SRAMF
57 GF Score
Price $0.44
GF Value $0.98
Valuation Significantly Undervalued
! 5 Warning Signs
View Full Analysis

What is Sisram Medical Total Stockholders Equity?

Sisram Medical SRAMF 57 Total Stockholders Equity is $479.9 Mil as of Dec. 2025. GuruFocus rates SRAMF with a GF Score™ of 57/100 and a GF Value™ of $0.98 (Significantly Undervalued). The stock has 5 warning signs investors should review.

Sisram Medical's Total Stockholders Equity for the quarter that ended in Dec. 2025 was $479.9 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Sisram Medical's Book Value per Share for the quarter that ended in Dec. 2025 was $1.02. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Sisram Medical's Debt-to-Equity for the quarter that ended in Dec. 2025 was 0.11.

Sisram Medical  (OTCPK:SRAMF) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Sisram Medical's Book Value per Share for the quarter that ended in Dec. 2025 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(479.852-0)/468.343
=1.02

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Sisram Medical's Debt-to-Equity for the quarter that ended in Dec. 2025 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(16.289 + 35.464) / 479.852
=0.11

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sisram Medical Total Stockholders Equity Related Terms

Sisram Medical Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Sisram Medical's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sisram Medical Total Stockholders Equity Chart

Sisram Medical Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 402.18 430.87 452.31 464.03 479.85

Sisram Medical Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 452.31 453.07 464.03 453.07 479.85
SRAMF
57GF Score
Sisram Medical Ltd SRAMF
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of $479.9 Mil mean?
Sisram Medical (SRAMF) has a Total Stockholders Equity of $479.9 Mil as of Dec. 2025. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Sisram Medical and its competitors.
Is Sisram Medical's Total Stockholders Equity too high?
Sisram Medical's current Total Stockholders Equity is $479.9 Mil. Overall, Sisram Medical has a GF Score™ of 57/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sisram Medical's Total Stockholders Equity compare to ABT and SYK?
Sisram Medical's Total Stockholders Equity of $479.9 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Medical Devices & Instruments company?
A good Total Stockholders Equity depends on the Medical Devices & Instruments industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Sisram Medical and its competitors. Sisram Medical's current Total Stockholders Equity is $479.9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sisram Medical stock overvalued right now?
Based on GuruFocus' analysis, Sisram Medical (SRAMF) is currently considered Significantly Undervalued. The stock's GF Value™ is $0.98, compared to a current price of $0.44 — trading 55.3% below its estimated fair value. The current Total Stockholders Equity is $479.9 Mil. Sisram Medical's overall GF Score™ is 57/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Sisram Medical (SRAMF), the current Total Stockholders Equity is $479.9 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sisram Medical (SRAMF) Overvalued in 2026?

Based on GuruFocus' analysis, Sisram Medical stock appears to be undervalued. The current stock price of $0.44 is trading 55.3% below its estimated GF Value™ of $0.98. GuruFocus considers Sisram Medical to be Significantly Undervalued.

Key valuation signals for SRAMF:

  • Total Stockholders Equity: $479.9 Mil
  • GF Value™: $0.98 vs. price of $0.44 (55.3% below fair value)
  • GF Score™: 57/100 with 5 warning signs

No single metric tells the full story. See the SRAMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sisram Medical Business Description

Other Exchanges 01696:Hong Kong
Address HaHarash Street 18, Ofek Building 15, Industrial Park, Caesarea, ISR, 3079895
Sisram Medical Ltd is an investment holding company specializing in medical technology for healthcare. The Company is involved in research, development, design, manufacture, sale and marketing of medical aesthetics and dental equipment, home use devices, injectables and cosmeceuticals products. The company's products include Soprano Titanium, Colibri technology, and others. Some of the company's brands are Alma, Soprano, Copulla, and LMNT. It operates through the following geographical segments: North America which is its key revenue generating market, Europe, Asia Pacific, Latin America, and the Middle East and Africa.
57GF Score

Get the complete analysis for SRAMF

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.44
Price
$0.98
GF Value